The past several decades of research in tumor immunology have revealed a strong link between tumor immunity and autoimmunity. This connection is first understood in the context of the extensive overlap between antigens expressed by a tumor and its normal tissue counterpart [1, 2]. The best-studied example of concurrent tumor immunity and autoimmunity is the development of vitiligo in association with melanoma. Vitiligo, or the autoimmune destruction of melanocytes, is an independent positive prognostic factor for melanoma patients [3-5], and its incidence is increased by certain immunotherapies that drive T cell responses to melanoma [6-8]. For years, autoimmunity has been viewed as a side effect of robust anti-tumor immunity. New research now demonstrates that autoimmune melanocyte killing also directly maintains T cell immunity to melanoma . The crucial role of autoimmunity in shaping anti-tumor immunity now informs the interpretation of immunotherapeutic responses in the lab and in the clinic. In this research perspective, we explore the history linking melanoma and vitiligo in patients, key experiments in animal models that have shaped our understanding of this relationship, and the characteristics of memory T cell responses that are governed by vitiligo. Finally, we discuss the importance of autoimmunity for the success of tumor immunotherapy.
Melanoma and vitiligo: A history of clinical correlations
Melanoma and vitiligo, despite diametrically opposed clinical manifestations, have been empirically linked for over 50 years with significant implications for patients. Melanoma, the outgrowth of transformed melanocytes, has long been recognized as a particularly aggressive cancer, with median survival for metastatic disease ranging between 6-11 months [10, 11]. Surgical treatment has been the standard of care for nearly 150 years . One of the earliest case-based observations linking vitiligo and melanoma was published in 1953, when a patient with a ‘melanosarcoma’ developed depigmented lesions , followed by a report in 1960 noting systemic depigmentation in a melanoma patient treated with radiation therapy . Four years later, Burdick and Hawk reported regression of cutaneous and visceral lesions – concurrent with the development of vitiligo – in a metastatic melanoma patient treated with Vaccinia virus . The following year, Smith and Sehlin reported the development of vitiligo in several melanoma patients with spontaneously regressing primary tumors . These papers were among the first to suggest that tumor immunity and autoimmunity were linked.
Beginning in the early 1970’s, studies began to suggest that vitiligo portended improved prognosis for melanoma patients. A small study of 11 patients reported that survival was slightly prolonged in metastatic melanoma patients with vitiligo, but concluded that data supporting a ‘direct relationship between the two conditions’ was still lacking . Several case studies continued to comment on the association between vitiligo and enhanced survival in melanoma patients, but without statistical support [18-20]. It wasn’t until 1983 that Nordlund and colleagues demonstrated significantly enhanced 5-year survival rates in melanoma patients with vitiligo . This was followed by a more extensive study by Bystryn and colleagues in 1987, which reached similar conclusions . However, these studies included a majority of patients with Stage I or II disease, and data from metastatic melanoma patients was lacking. Recently, in a large cohort of metastatic melanoma patients, Quaglino and colleagues reported that vitiligo was an independent positive prognostic factor correlating with significantly enhanced 5-year survival, providing further support for long-reported clinical observations . Thus vitiligo is clearly associated with improved immunity to melanoma in patients, though the mechanisms linking these phenomena remain a subject of active investigation.
Mechanisms of melanoma-associated vitiligo in humans
As the correlative relationship between vitiligo and melanoma was beginning to be described, the role of the immune response in melanocyte destruction was also under investigation. In 1971, Milton et al. argued that spontaneous regressions of primary melanomas implied active anti-tumor immunity, and suggested that associated vitiligo was also a manifestation of this immune response . Supporting this argument, lymphocytic infiltrates were observed in melanomas of several vitiligo-affected patients that underwent spontaneous regression [16, 21]. The infiltration of lymphocytes into both melanoma and vitiligo lesions, as well as spontaneous regression of primary melanoma tumors , led to the hypothesis in 1971 that depigmentation was immune-mediated . Over the next decade, several groups postulated the ‘tempting’ idea that melanoma-associated vitiligo was the result of a cross-reactive immune response [3, 22, 23]. However, early studies conceded that other non-immunological mechanisms may be in play, and alternatives to immune mediated pathology were postulated . Theories suggested that toxins from nerves, free radical scavenging, or byproducts from melanin manufacturing itself resulted in the death of melanocytes or the disabling of melanin production [25, 26].
Today, overwhelming genetic and immunologic evidence supports the autoimmune etiology of vitiligo in melanoma patients. Studies by Houghton et al. in the early 1980’s revealed that melanoma cells express a family of differentiation antigens that are shared by normal melanocytes [1, 27]. This family of proteins includes tyrosinase and related proteins TRP-1 (gp75) and TRP-2 (dopachrome tautomerase), as well as gp100, and MART-1 (Melan-A); each of which plays a critical role in melanin synthesis . Melanocyte differentiation antigens have since formed the basis for analyzing antigen-specific immune responses to both melanoma and melanocytes .
Currently, there are two major proposed mechanisms of vitiligo pathogenesis; one antibody based, and the other T cell based . Autoantibodies recognizing tyrosinase, TRP-1, and TRP-2, have been detected in the sera of melanoma patients and vitiligo patients . The total levels of antibodies directed against pigmented cells have also been shown to correlate with the extent of vitiligo in melanoma-free patients . Additionally, antibodies found in the sera of vitiligo patients have been shown to lyse melanocytes and melanoma cells in vitro . However, data supporting antibody-mediated vitiligo in melanoma patients have been limited. Compared with vitiligo patients, melanoma patients with vitiligo have been shown to have similar titers of antibodies to TRP-2 , although they have significantly lower titers of antibodies directed against whole melanoma cells and tyrosinase [34, 35].
On the other hand, there is substantial evidence that CD8 T cells mediate melanoma-associated vitiligo. CD8 T cells taken from lesions of vitiligo patients have been shown to kill melanoma cells ex vivo , and CD8 T cells from both tumors and peripheral blood of melanoma patients have been shown to kill normal melanocytes . In melanoma patients with vitiligo, clonotypically identical T cells were found in both the tumor and surrounding depigmented lesions . It has been shown that the majority of cells infiltrating these lesions are CD8+ T cells that recognize both normal melanocytes and melanoma cells . Accordingly, after therapeutically transferring MART-1 specific CD8 T cells to a melanoma patient, transferred cells were found to accumulate in depigmented lesions that developed as a result of therapy . CD4 T cells have also been found to infiltrate vitiligo lesions, although less is known about melanocyte-specific CD4 T cell responses [36, 41]. Two recent studies have identified increased levels of IL-17 in both the serum and tissue of vitiligo patients [42, 43], which may suggest CD4 T cell involvement. Therefore significant clinical evidence supports the theory that melanoma-associated vitiligo is a CD8 T cell mediated phenomenon, although antibodies and/or CD4 T cells may also play roles.
Lessons learned from animal models
Concurrent with these efforts to understand the relationship between melanoma and vitiligo in the clinic, a wealth of mechanistic studies has been undertaken in the laboratory. Inbred C57BL/6 mice and the syngeneic, transplantable, B16 mouse melanoma model have greatly facilitated this work. Hara et al. were the first to report the outgrowth of white hair in black mice upon treatment with the TA99 monoclonal antibody to TRP-1 . Mice treated with TA99 were also protected against B16 melanoma, showing for the first time that immune responses against shared melanoma/melanocyte antigens could concurrently mediate tumor immunity and autoimmunity . Since this seminal work, studies have turned largely to inducing CD8 T cell responses, and several MHC I-restricted epitopes from gp100 , TRP-2 , tyrosinase , and TRP-1  have since been employed as targets of melanoma vaccines and cellular therapies. T cell receptor transgenic mice with specificity for melanocyte antigens have also provided a valuable tool for understanding mechanisms driving rejection of established melanoma and the induction of vitiligo [49-52]. Below we discuss the experiments in mice that have most contributed to our understanding of tumor immunity and concomitant autoimmunity.
Primary T cell responses to melanoma and melanocytes
The major focus of melanoma immunotherapy over the past 20 years has been on breaking T cell tolerance to melanocyte differentiation antigens, and vitiligo is a common occurrence with such therapies. The administration of altered melanocyte antigens has been one strategy used to overcome tolerance. DNA vaccines encoding altered forms of melanocyte differentiation antigens, such as xenogenic gp100 [53, 54], epitope enriched TRP-1 , and randomly mutated TRP-2 , have each proven effective at priming CD8 T cell responses, resulting in protective immunity against melanoma and concomitant vitiligo. Altered self-antigens have also been highly effective when administered in the context of viral vaccine vectors , or as heteroclitic peptides in combination with multifactorial adjuvants such as anti-CD40 and TLR agonists [57, 58].
Other studies have shown that altered antigen is not required to break tolerance to melanocyte antigens if sufficient inflammatory and/or costimulatory signals are present. For example, irradiated B16 tumor cells producing GM-CSF (GVAX) combined with a blocking monoclonal antibody to CTLA-4 breaks tolerance to melanocyte differentation antigens, resulting in protective anti-tumor immunity and vitiligo . Treatment with monobenzone, a compound which results in melanocyte killing through haptenization of tyrosinase and induction of melanocyte autophagy , also leads to rejection of B16 melanoma tumors and the development of vitiligo when combined with TLR agonists . Lymphopenia-induced homeostatic T cell proliferation in the context of a progressive melanoma, and the absence of CD4+CD25+ regulatory T cells (Treg), is sufficient to break tolerance and induce vitiligo, likely due to the removal of both suppression and homeostatic cytokine sinks . Thus, inflammatory, costimulatory, and/or cytokine stimuli may be sufficient to break tolerance to antigens expressed by melanoma cells or dying melanocytes.
Further, our own work has shown that, even in the absence of overt inflammatory stimuli, disruption of regulatory T cell-mediated suppression is sufficient to overcome tolerance to melanoma-expressed self-antigens. In B16 tumor-bearing mice, we found that depletion of Treg cells by treatment with anti-CD4 breaks CD8 T cell tolerance to TRP-2 and gp100 . These tumor-primed CD8 T cells, although unable to control growth of established primary B16 melanoma tumors, provide systemic concomitant immunity against B16 re-challenge . Furthermore, following Treg depletion, we showed that surgical excision of intradermal B16 melanoma tumors resulted in a majority of mice developing CD8 T cell-mediated vitiligo [9, 63]. Interestingly, trauma to the skin has previously been shown to provide non-specific inflammation that is critical for vitiligo induction [56, 64]. Whereas surgical tumor excision was employed in our model as a means for prolonging host survival, it may also play a role in initiating vitiligo. In fact, we typically observe vitiligo first at the site of surgery , often in a pattern that mimics the incision site with striking accuracy (Figure 1). Taken together, these studies indicate the existence of multiple pathways for overcoming T cell tolerance to melanoma and inducing autoimmunity against melanocytes.
Figure 1: Vitiligo initiation at site of surgery. Mice bearing intradermal B16 tumors on the right flank were treated by anti-CD4 monoclonal antibody to deplete regulatory T cells, followed by surgical tumor excision, as we have previously described . 3 weeks after surgery, vitiligo was observed along the surgical incision line (dotted line), and at points where surgical clips had pierced the skin (arrows).
In recent years, T cell receptor transgenic (TCR Tg) mouse models have provided crucial new insights into mechanisms driving vitiligo and effective melanoma immunotherapy. The pmel-1 CD8 TCR Tg mouse was the first such model, possessing a TCR specific for gp10025-33 in the context of Db . The pmel T cell clone was originally raised by vaccination of wild-type (gp100-sufficient) mice with human gp100, and therefore is thought to have low to moderate avidity . Pmel mice begin to develop mild, spontaneous vitiligo at ~10 weeks of age (KTB and MJT, unpublished observations). Moreover, adoptive transfer of in vitro activated pmel cells in conjunction with human gp100 viral vaccination, lymphodepletion, high dose IL-2, and/or TLR stimulation induces profound vitiligo and regression of established melanoma in recipient mice [49, 65-67].
In addition to pmel mice, a TRP-2 specific TCR Tg mouse with specificity for TRP-2180-188 (termed Clone 37) was more recently generated . These mice do not develop spontaneous vitiligo, and adoptive transfer of naïve Tg T cells fails to induce rejection of established B16 tumors . The low potency of these cells may be a reflection of a lower avidity TCR, as Clone 37 was originally raised by vaccination of wild-type mice with murine TRP-2 . A third model with specificity for Tyr369-377 in the context of HLA-A2.1 expresses the TCR from a CD8 T cell clone that was isolated following vaccination of albino (tyrosinase-deficient) HLA-A2.1 transgenic mice [68, 69]. In contrast to pmel and Clone 37 mice, Tyr369-377 TCR Tg mice develop robust vitiligo, with symptoms and kinetics similar to human disease, suggesting that they possess a higher avidity TCR .
Interestingly, high-avidity CD4 T cells are also capable of mediating vitiligo, which may relate to the fact that both melanocytes and melanoma cells can express MHC II molecules [70, 71]. A CD4 TCR Tg model with specificity for TRP-1113-127 was developed from immunized TRP-1-/- mice . In a wild-type (TRP-1 sufficient) background, TCR transgene expression results in T cell activation and vitiligo development , however, these T cells remain naïve on a TRP-1-/- background . Adoptive transfers of low numbers of naïve TRP-1-specific T cells into wild-type mice results in overt vitiligo and potent rejection of established B16 melanoma when given in combination with vaccine and IL-2 , irradiation and anti-CTLA-4 , or in lymphopenic hosts . Taken together, these TCR Tg models suggest that the development of spontaneous vitiligo in unmanipulated hosts may be dependent on TCR avidity for self-peptide/MHC. These models have proven to be valuable tools for understanding the mechanisms behind effective melanoma adoptive T cell therapy.
Maintenance of memory T cell responses to melanoma and melanocytes
Although generating robust primary CD8 T cell responses to melanoma has been a subject of intense investigation, less emphasis has been placed on understanding the maintenance of T cell memory, particularly in the context of autoimmune disease. Studies have demonstrated a correlation between long-lived protection against melanoma and depigmentation in experimental models [49, 63, 65, 67], although vitiligo-affected and unaffected mice had not been directly compared with regards to the quality of CD8 T cell memory. Furthermore, whereas the most effective immunotherapies against established B16 tumors clearly generate vitiligo [49, 73], it has remained uncertain whether autoimmunity confers long-term benefits for anti-tumor immunity. Research in our laboratory demonstrated that mice treated by regulatory T cell depletion developed post-surgical CD8 T cell memory responses to TRP-2 and gp100 . Because approximately half of these mice developed vitiligo, this model has enabled investigation of the unique features of T cell memory in hosts with concomitant autoimmunity.
Our recent studies reveal that CD8 memory T cells in vitiligo-affected hosts are potent anti-tumor effectors with key defining characteristics. First, vitiligo-affected hosts maintained gp100 and TRP-2-specific memory CD8 T cells at 10-fold larger frequencies, as compared with unaffected hosts . Second, gp100-specific T cells in vitiligo-affected mice developed an overwhelmingly effector memory (TEM) phenotype, in contrast to a predominantly central memory (TCM) phenotype in hosts without vitiligo . In accordance with their TEM phenotype, gp100-specific T cells in mice with vitiligo homed preferentially to peripheral tissue sites. Although chronically activated, these cells did not display phenotypic or functional signs of exhaustion, even more than one year after priming . This non-exhausted phenotype was not expected, as it had long been speculated that exposure to self-antigen would drive memory T cells to exhaustion and deletion, which is observed in chronic viral infection models . However, vitiligo-affected mice also exclusively maintained long-term CD8 T cell-mediated protection against a secondary B16 tumor challenge, confirming the protective function of these cells . Studies comparing memory CD8 T cell populations for adoptive T cell therapy had previously led to the hypothesis that TCM cells are more potent anti-tumor effectors than TEM cells . Our studies show that large populations of non-exhausted TEM cells also provide durable tumor protection— a unique feature of hosts with autoimmunity.
Lessons learned from melanocyte-deficient mice
Our comparison of T cell memory in vitiligo-affected and unaffected mice demonstrated a clear correlation between autoimmunity and the maintenance of robust, protective, T cell responses to melanoma. However, these studies did not address whether vitiligo directly contributed to T cell immunity. To specifically answer this question, we established the Wsh mouse model of melanocyte deficiency as a model of vitiligo insufficiency (Figure 2) . Due to a mutation in the regulatory region of c-kit, Wsh mice are overwhelmingly melanocyte deficient, and appear almost completely white, with the exception of the retina [75, 76]. Traditionally used as a mast-cell deficient model, Wsh mice had not been previously employed as a model of vitiligo insufficiency . However, these mice have proven to be a useful tool to investigate the role of melanocyte destruction in the maintenance of melanoma T cell responses to melanoma.
Figure 2: Wsh mice as a model of vitiligo insufficiency. A vitiligo affected mouse (left) and a Wsh mouse (right).
Using the Wsh model, we have recently found that the absence of melanocytes impairs the development of T cell memory to melanoma . Our data show that Wsh mice prime gp100-specific CD8 T cells that are equivalent in frequency and phenotype to wild-type hosts. However, they are unable to develop the robust effector memory T cell responses that characterize hosts with vitiligo . Instead, melanocyte-deficient mice develop small, TCM populations, similar to those in vitiligo-unaffected wild-type mice . Moreover, when gp100-specific CD8 T cells were first primed in tumor-bearing Wsh mice, and then adoptively transferred into melanocyte-sufficient mice with vitiligo, the unique TEM phenotype and homing function of these T cells was restored . Thus, the fate of melanoma antigen-specific CD8 T cells was not pre-determined at priming, but rather was altered by exposure to melanocyte destruction. Additionally, robust populations of gp100-specific TEM cells could be rescued in Wsh mice by exogenous supplementation of gp100 antigen, confirming that melanocyte antigen is required for the maintenance of T cell memory . These studies establish that melanocyte antigens liberated by vitiligo drive the maintenance of a unique, functional, antigen-dependent memory T cell response to melanoma . The fact that vitiligo directly sustains immune responses to melanoma provides new insight into a phenomenon that has long been observed in the clinic and the laboratory.
Shared melanoma/melanocyte antigens vs. tumor-specific antigens
While we have emphasized the role of autoimmunity in maintaining anti-tumor immunity, it is important to differentiate between responses directed against shared melanoma/melanocyte antigens and those directed against tumor-specific antigens. In melanoma patients, CD8 T cell epitopes from NY-ESO-1 , MAGE , and BRAFV600E , have been reported, and may represent natural tumor-specific antigens that can be targeted for protective anti-tumor immunity without vitiligo. Accordingly, our laboratory has recently shown that protective memory CD8 T cell responses to B16 melanoma can be generated in the complete absence of vitiligo if rejection antigens are tumor-specific . In B16 tumor-bearing mice treated by surgery and a stimulatory mAb against the glucocorticoid-induced TNFR family-related receptor (GITR), we found that protective T cell responses are preferentially directed against tumor-specific antigens . This was evidenced by the fact that mice avidly rejected B16 melanoma re-challenge, but demonstrated no cross-protection against JBRH melanoma. Accordingly, GITR stimulation did not break T cell tolerance to melanocyte differentiation antigens, or induce vitiligo, although it resulted in high-avidity T cell responses against B16 tumor-expressed ovalbumin (OVA) as a model tumor-specific antigen . The mechanisms whereby GITR stimulation skews T cell immunity to tumor-specific antigens remains under investigation, however these data provide evidence that protective CD8 memory T cell responses to melanoma can be generated in the absence of autoimmunity.
There is also evidence that T cell memory to tumor-specific antigens more closely mimics classical memory T cell responses described in acute viral infection models . In studies investigating CD8 T cell responses generated by Treg depletion and surgery in mice bearing B16-OVA tumors, we found that OVA-specific CD8 T cells develop into a small but functional memory T cell population, with a predominantly TCM phenotype . This was true regardless of the vitiligo status of the host . Generating such long-lived T cell memory against tumor-specific antigens will be particularly important for tumors of essential organs, such as the liver or pancreas, where autoimmune responses cannot be tolerated.
For melanoma, we propose that two major types of protective memory T cell responses can be generated, depending on the antigen-specificity of the response (Figure 3). The first type, directed against shared melanoma/melanocyte antigens, has a more stringent set of requirements for T cell priming. However, if T cells efficiently mediate tumor rejection and induce vitiligo, they will develop into a unique, functional memory T cell response that relies on melanocyte destruction for its ongoing maintenance. Alternatively, a second type of memory, directed against tumor-specific antigens, can be likened to T cell responses against foreign antigens. During the effector phase, these T cells will target melanoma cells without killing healthy melanocytes. Subsequently, following melanoma clearance, they develop into classical, antigen-independent T cell memory. As both types of memory would be expected to provide durable protection against melanoma, such a model can explain how long-term immunity to cancer can be achieved either in the presence or absence of autoimmunity.
Figure 3: Pathways to protective memory CD8 T cell responses to melanoma. (Top) Generation of CD8 T cell responses to shared melanoma/melanocyte antigens. Factors that contribute to priming of are listed at left. One or more of these factors leads to the breaking of tolerance (indicated by red line), resulting in effective primary CD8 T cell responses against melanoma that cross-react against healthy melanocytes and induce vitiligo during the effector phase. Ongoing melanocyte destruction provides antigen to support the memory phase of the response; unique characteristics of vitiligo-dependent memory T cells are indicated at right. (Bottom) Generation of CD8 T cell responses against tumor-specific antigens expressed by melanoma. Factors contributing to priming are listed at left; there is no need to overcome tolerance to generate primary CD8 T cell responses against tumor-specific antigens. In the effector phase, CD8 T cells directed against tumor-specific antigens kill melanoma cells but do not cross-react with melanocytes, therefore vitiligo does not occur. During the memory phase, CD8 T cells directed against tumor specific antigens possess classical memory T cell characteristics, indicated at right.
Shedding new light on therapy-induced vitiligo in patients
Vitiligo has been more difficult to generate in humans than in mice, although certain immunotherapies clearly promote its development. In a large retrospective analysis of 374 metastatic melanoma patients treated with high-dose IL-2, a total of 84 patients (22%) developed treatment-related vitiligo, although in patients with objective clinical responses the incidence of vitiligo was nearly 50% . Another study found that IL-2 and GM-CSF maintenance therapy induced vitiligo in a striking 43% of patients (21 out of 49), who demonstrated significantly enhanced survival as compared with unaffected patients . Combination of high-dose IL-2 with CD8 adoptive T cell therapy (ACT) and lymphodepleting chemotherapy has received much attention in recent years. In a small study, this ACT regimen induced vitiligo in 5 out of 13 melanoma patients, all of whom demonstrated significant tumor regression . More recent data demonstrate that myeloablative regimens further improve the efficacy of ACT, resulting in a 70% metastatic melanoma response rate , however, the effects of such therapy on vitiligo development have not yet been reported. These studies demonstrate that high rates of vitiligo can be achieved with certain types of immunotherapy, and may further imply that therapy-induced vitiligo promotes protective immune responses to melanoma. Future investigation of melanoma/melanocyte antigen-specific T cells in surviving vitiligo-affected and unaffected patients should provide further insights into the types of T cell memory that mediate tumor protection in humans.
Vitiligo induction as a crucial component of melanoma tumor immunotherapy is by no means a new concept. In 1977, Lerner and Nordlund suggested that vitiligo should be induced in patients after resection of primary melanoma, and further proposed the use of melanocytotoxic compounds such as monobenzone [19, 81]. Monobenzone therapy was in fact used on a small cohort of late-stage melanoma patients in 1986 and, while 11 out of 17 treated patients had complete responses, their vitiligo status was not reported . No further trials have investigated the therapeutic efficacy of vitiligo induction in melanoma patients, however several groups have resurrected the hypothesis as of late [30, 36, 61, 83]. Recent in vitro studies by van den Boorn and colleagues have elucidated the mechanism by which monobenzone results in human melanocyte cell death and the downstream initiation of anti-melanocyte CD8 T cell responses . These studies support animal data from the same group, where monobenzone and TLR agonist treatment of mice with established B16 tumors required CD8 T cells for efficacy . Other methods of specifically targeting melanocytes for destruction, such as anti-TRP-1 mAb  and tert-butyl-phenol (TBP)  could be used similarly, or as an adjuvant therapy following surgical tumor removal. New mechanistic insights into the importance of vitiligo clearly support future investigation of vitiligo induction as a component of combination melanoma immunotherapies.
Finally, the development of melanocyte-unrelated autoimmune disease in melanoma patients warrants comment. In melanoma patients receiving adjuvant IFN-α therapy, generalized autoimmunity has been reported to correlate with clinical responses . Similarly, following treatment with ipilimumab (anti-CTLA-4), over a third of total responding patients developed autoimmunity, although not limited to vitiligo . While there is no evidence that melanocyte-unrelated autoimmune disease can directly promote melanoma-specific T cell responses, generalized autoimmunity may provide particular inflammatory and/or danger signals that help to overcome tolerance to self-antigens expressed by tumors. Specific attributes of tissue-specific and non-specific autoimmune disease that contribute to anti-tumor immunity are only beginning to be understood, and will require future investigation.
The development of vitiligo clearly portends enhanced survival in melanoma patients, and recent experimental data has now provided a new understanding of this phenomenon. Vitiligo is still reported as an ‘adverse event’ during clinical trial evaluation , however, this thinking is now shifting. Future studies will be necessary to address whether durable clinical responses in melanoma patients (e.g. those receiving adoptive T cell therapies) are supported by the concurrent progression of vitiligo. More broadly, given the potential efficacy of therapies that target shared tumor/self antigens, we propose that driving tissue-specific autoimmune disease is both feasible and desirable for tumors of non-essential organs (e.g. melanoma, breast, prostate, and ovarian cancer). In conjunction with promising new cancer therapies, harnessing the supportive role of autoimmunity may tip the scales against tumor growth and in favor of lasting anti-tumor immunity.
Support for this work was provided by the NIH grant R01 CA120777 to MJT. KTB was also supported by NIH T32 A107363 and the Joanna M. Nicolay Melanoma Foundation.
The authors would like to thank Marc Ernstoff, Ed Usherwood, David Mullins, Jake Reder, and Shannon Steinberg for their thoughtful input and critical reading of this manuscript.
1. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med. 1982; 156:1755-1766.
2. Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev. 2002; 188:122-135.
3. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983; 9:689-696.
4. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol. 1987; 123:1053-1055.
5. Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, Fierro MT, Savoia P, Bernengo MG. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol. 2009; 21:409-414.
6. Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O’Day SJ. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol. 2006; 126:2658-2663.
7. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298:850-854.
8. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001; 19:3477-3482.
9. Byrne KT, Cote AL, Zhang P, Steinberg SM, Guo Y, Allie R, Zhang W, Ernstoff MS, Usherwood EJ, Turk MJ. Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest. 2011; 121:1797-1809.
10. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364:2119-2127.
11. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711-723.
12. Cooper S: The first lines of the theory and practice of surgery; including priniciple operations., vol. 1, 7 edn. London: Williard Parker; 1844.
13. Matsuzawa T, Watanabe M, Kondo R. Case of leukoderma in X-Ray portion of patient with Melanosarcoma. Shinshu Med J. 1953; 2:254-258.
14. Karcher K. Systematiesierte Depigmentierung bei strahlenbehandelten Melanomen. Dermatologica. 1960; 120:255-263.
15. Burdick KH, Hawk WA. Vitiligo in a Case of Vaccinia Virus-Treated Melanoma. Cancer. 1964; 17:708-712.
16. Smith JL, Jr., Stehlin JS, Jr. Spontaneous regression of primary malignant melanomas with regional metastases. Cancer. 1965; 18:1399-1415.
17. Milton GW, McCarthy WH, Carlon A. Malignant melanoma and vitiligo. Australas J Dermatol. 1971; 12:131-142.
18. Gregor RT. Vitiligo and malignant melanoma: a significant association? S Afr Med J. 1976; 50:1447-1449.
19. Nordlund JJ, Lerner AB. Vitiligo and melanoma. Arch Dermatol. 1979; 115:636.
20. Donaldson RC, Canaan SA, Jr., McLean RB, Ackerman LV. Uveitis and vitiligo associated with BCG treatment for malignant melanoma. Surgery. 1974; 76:771-778.
21. Copeman PW, Lewis MG, Phillips TM, Elliott PG. Immunological associations of the halo naevus with cutaneous malignant melanoma. Br J Dermatol. 1973; 88:127-137.
22. Pantoja E, Wendth AJ, Beecher TS. Perilesional vitiligo in melanoma. Cutis. 1977; 19:51-53.
23. Koh HK, Sober AJ, Nakagawa H, Albert DM, Mihm MC, Fitzpatrick TB. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol. 1983; 9:696-708.
24. Barnes L, Nordlund JJ. Depigmentation: its significance in patients with melanoma. Clin Dermatol. 1989; 7:66-73.
25. Abu Tahir M, Pramod K, Ansari SH, Ali J. Current remedies for vitiligo. Autoimmun Rev. 9:516-520.
26. Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev. 2007; 6:138-142.
27. Houghton AN. The serological analysis of human cancer. Identification of differentiation antigens on melanoma and melanocytes. Prog Clin Biol Res. 1983; 119:199-205.
28. Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol. 2006; 90:215-241.
29. Michelsen D. The Double Strike Hypothesis of the vitiligo pathomechanism: new approaches to vitiligo and melanoma. Med Hypotheses. 2010; 74:67-70.
30. Ram M, Shoenfeld Y. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann N Y Acad Sci. 2007; 1110:410-425.
31. Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patients’ sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol. 1988; 90:783-789.
32. Naughton GK, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol. 1986; 15:978-981.
33. Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, Hoon DS. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol. 1998; 111:1034-1039.
34. Merimsky O, Shoenfeld Y, Yecheskel G, Chaitchik S, Azizi E, Fishman P. Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother. 1994; 38:411-416.
35. Merimsky O, Baharav E, Shoenfeld Y, Chaitchik S, Tsigelman R, Cohen-Aloro D, Fishman P. Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol Immunother. 1996; 42:297-302.
36. Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, Nishimura MI, Das PK, Luiten RM, Le Poole IC. Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev. 2006; 5:486-492.
37. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med. 1993; 177:989-998.
38. Becker JC, Guldberg P, Zeuthen J, Brocker EB, Straten PT. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol. 1999; 113:1033-1038.
39. Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol. 2001; 117:1464-1470.
40. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000; 192:1637-1644.
41. Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res. 2003; 16:254-260.
42. Bassiouny DA, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol. 2010; 36:292-297.
43. Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N, Sullivan-Whalen M, Gilleaudeau P, Cohen JA, Krueger JG. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One. 2011; 6:e18907.
44. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med. 1995; 182:1609-1614.
45. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998; 188:277-286.
46. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997; 185:453-459.
47. Goldberg SM, Bartido SM, Gardner JP, Guevara-Patino JA, Montgomery SC, Perales MA, Maughan MF, Dempsey J, Donovan GP, Olson WC, Houghton AN, Wolchok JD. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res. 2005; 11:8114-8121.
48. Guevara-Patino JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, Cohen AD, Merghoub T, Wolchok JD, Houghton AN. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest. 2006; 116:1382-1390.
49. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003; 198:569-580.
50. Singh V, Ji Q, Feigenbaum L, Leighty RM, Hurwitz AA. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. J Immunother. 2009; 32:129-139.
51. Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med. 2000; 191:1221-1232.
52. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008; 112:362-373.
53. Gold JS, Ferrone CR, Guevara-Patino JA, Hawkins WG, Dyall R, Engelhorn ME, Wolchok JD, Lewis JJ, Houghton AN. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol. 2003; 170:5188-5194.
54. Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB, Srinivasan R, Houghton AN, Lewis JJ. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery. 2000; 128:273-280.
55. Engelhorn ME, Guevara-Patino JA, Noffz G, Hooper AT, Lou O, Gold JS, Kappel BJ, Houghton AN. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med. 2006; 12:198-206.
56. Lane C, Leitch J, Tan X, Hadjati J, Bramson JL, Wan Y. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res. 2004; 64:1509-1514.
57. Ahonen CL, Wasiuk A, Fuse S, Turk MJ, Ernstoff MS, Suriawinata AA, Gorham JD, Kedl RM, Usherwood EJ, Noelle RJ. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood. 2008; 111:3116-3125.
58. Cho HI, Celis E. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res. 2009; 69:9012-9019.
59. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999; 190:355-366.
60. van den Boorn JG, Picavet DI, van Swieten PF, van Veen HA, Konijnenberg D, van Veelen PA, van Capel T, Jong EC, Reits EA, Drijfhout JW, Bos JD, Melief CJ, Luiten RM. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol. 2011; 131:1240-1251.
61. van den Boorn JG, Konijnenberg D, Tjin EP, Picavet DI, Meeuwenoord NJ, Filippov DV, van der Veen JP, Bos JD, Melief CJ, Luiten RM. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One. 2010; 5:e10626.
62. Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, Zhang L, Gajewski TF. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008; 14:3156-3167.
63. Zhang P, Cote AL, de Vries VC, Usherwood EJ, Turk MJ. Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res. 2007; 67:6468-6476.
64. Redondo P, del Olmo J, Lopez-Diaz de Cerio A, Inoges S, Marquina M, Melero I, Bendandi M. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol. 2007; 127:1673-1680.
65. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest. 2007; 117:2197-2204.
66. Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ, Restifo NP, Smyth MJ, Darcy PK, Kershaw MH. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother. 2011; 60:671-683.
67. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005; 102:9571-9576.
68. Nichols LA, Chen Y, Colella TA, Bennett CL, Clausen BE, Engelhard VH. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J Immunol. 2007; 179:993-1003.
69. Gregg RK, Nichols L, Chen Y, Lu B, Engelhard VH. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol. 2010; 184:1909-1917.
70. Le Poole IC, Mutis T, van den Wijngaard RM, Westerhof W, Ottenhoff T, de Vries RR, Das PK. A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol. 1993; 151:7284-7292.
71. Le Drean E, Gervois N, Diez E, Semana G, Dreno B, Jotereau F. HLA class II-restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma-infiltrating lymphocytes. Eur J Immunol. 1995; 25:2732-2736.
72. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med. 2010; 207:651-667.
73. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010; 207:637-650.
74. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010; 22:223-230.
75. Cable J, Jackson IJ, Steel KP. Mutations at the W locus affect survival of neural crest-derived melanocytes in the mouse. Mech Dev. 1995; 50:139-150.
76. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol. 2005; 167:835-848.
77. Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, van Belle P, Hotz S, Elder DE, Marincola FM, Schuchter L, Guerry D, Czerniecki BJ, Herlyn D. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res. 2006; 66:3287-3293.
78. Cote AL, Zhang P, O’Sullivan JA, Jacobs VL, Clemis CR, Sakaguchi S, Guevara-Patino JA, Turk MJ. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol. 2011; 186:275-283.
79. Kaech SM, Wherry EJ. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity. 2007; 27:393-405.
80. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26:5233-5239.
81. Lerner AB, Nordlund JJ. Should vitiligo be induced in patients after resection of primary melanoma. Arch Dermatol. 1977; 113:421.
82. Vlock DR, DerSimonian R, Kirkwood JM. Prognostic role of antibody reactivity to melanoma. J Clin Invest. 1986; 77:1116-1121.
83. Hariharan V, Toole T, Klarquist J, Mosenson J, Longley BJ, Le Poole IC. Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment. Melanoma Res. 2011; 21:115-126.
84. Patel D, Balderes P, Lahiji A, Melchior M, Ng S, Bassi R, Wu Y, Griffith H, Jimenez X, Ludwig DL, Hicklin DJ, Kang X. Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. Hum Antibodies. 2007; 16:127-136.
85. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354:709-718.
86. Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, Yellin M, Weber JS. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011; 17:896-906.